Abstract
Neurotransmitter plasma membrane transporters do have much more to perform than simply terminating synaptic transmission and replenishing neurotransmitter pools. Findings in the past decade have evidenced their function in maintaining physiological synaptic excitability, and their actions in critical or pathological conditions, also. Conclusively these findings indicated a previously unrecognized role for neurotransmitter plasma membrane transporters in both, synaptic and nonsynaptic signaling. Major inhibitory and excitatory neurotransmitters within the brain, GABA and Glu, have long been considered to operate through independent systems (GABAergic or Gluergic), each of them characterized by its own localization, function and dedicated GABAergic or Gluergic cell phenotypes. Recent advances, however, have challenged this long-standing paradigm. Localization of GABA in Gluergic terminals and Glu in GABAergic cells were reported. Specific plasma membrane transporters for GABA and Glu are also co-localized in different brain areas. Although, their role in regulating each others signal is still far from being understood, emerging lines of evidence on interplaying GABAergic and Gluergic processes through plasma membrane transporters opens up a new avenue in the field of more specific therapeutic intervention.
Keywords: Localization of GABA and Glu transporters, reversed mode of transport, amino acid ergot derivatives, surface expression, nonsynaptic signaling, Zn2+ ion
Current Topics in Medicinal Chemistry
Title: Role for GABA and Glu Plasma Membrane Transporters in the Interplay of Inhibitory and Excitatory Neurotransmission
Volume: 6 Issue: 10
Author(s): Laszlo Heja, Kinga Karacs and Julianna Kardos
Affiliation:
Keywords: Localization of GABA and Glu transporters, reversed mode of transport, amino acid ergot derivatives, surface expression, nonsynaptic signaling, Zn2+ ion
Abstract: Neurotransmitter plasma membrane transporters do have much more to perform than simply terminating synaptic transmission and replenishing neurotransmitter pools. Findings in the past decade have evidenced their function in maintaining physiological synaptic excitability, and their actions in critical or pathological conditions, also. Conclusively these findings indicated a previously unrecognized role for neurotransmitter plasma membrane transporters in both, synaptic and nonsynaptic signaling. Major inhibitory and excitatory neurotransmitters within the brain, GABA and Glu, have long been considered to operate through independent systems (GABAergic or Gluergic), each of them characterized by its own localization, function and dedicated GABAergic or Gluergic cell phenotypes. Recent advances, however, have challenged this long-standing paradigm. Localization of GABA in Gluergic terminals and Glu in GABAergic cells were reported. Specific plasma membrane transporters for GABA and Glu are also co-localized in different brain areas. Although, their role in regulating each others signal is still far from being understood, emerging lines of evidence on interplaying GABAergic and Gluergic processes through plasma membrane transporters opens up a new avenue in the field of more specific therapeutic intervention.
Export Options
About this article
Cite this article as:
Heja Laszlo, Karacs Kinga and Kardos Julianna, Role for GABA and Glu Plasma Membrane Transporters in the Interplay of Inhibitory and Excitatory Neurotransmission, Current Topics in Medicinal Chemistry 2006; 6 (10) . https://dx.doi.org/10.2174/156802606777323656
DOI https://dx.doi.org/10.2174/156802606777323656 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Endocannabinoids in the Central Nervous System: From Neuronal Networks to Behavior
Current Drug Targets - CNS & Neurological Disorders Anti-Nociceptive and Anti-Inflammatory Effects of Stem Bark Extract of <i>Ficus Capensis</i> Thunb (Moraceae) by Bioactivity Fractionation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature
Current Drug Safety Triazino-caffeine Derivatives by Intramolecular Cyclization: Synthesis, Characterization and Antimicrobial Studies
Letters in Organic Chemistry Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets The Intestinal Absorption Mechanism of Gabapentin Makes it Appropriate for Gastroretentive Delivery
Current Clinical Pharmacology Levofloxacin-Induced Delirium in a Patient Suffering from Schizoaffective Disorder and Multiple Sclerosis
Current Drug Safety Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research An Effective Brain Imaging Biomarker for AD and aMCI: ALFF in Slow-5 Frequency Band
Current Alzheimer Research Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued)